Maximum Recommended Dose of Cyclosporine
The maximum recommended dose of cyclosporine is 5 mg/kg/day for most indications, with some protocols allowing up to 6 mg/kg/day in psoriasis for short-term use, though doses above 5 mg/kg/day carry substantially increased nephrotoxicity risk.
Dose Recommendations by Indication
Nephrotic Syndrome (FSGS/MCD)
- Starting dose: 100 mg/m²/day (approximately 3-5 mg/kg/day) in two divided doses 1, 2
- Maximum dose: 150 mg/m²/day (approximately 5 mg/kg/day) 1
- Critical caveat: Upper dose limits have not been definitively established, but nephrotoxicity risk increases substantially above 150 mg/m²/day 1
- Target trough level (C0): <150 ng/mL 1
The KDIGO guidelines specifically recommend cyclosporine at 3-5 mg/kg/day for steroid-resistant FSGS, given in divided doses for at least 4-6 months 2. Studies in this population used doses ranging from 3-6 mg/kg/day, with the majority showing efficacy at 3.5-5 mg/kg/day 1.
Psoriasis
- Starting dose: 2.5 mg/kg/day in two divided doses 3, 4
- Maximum dose: 4 mg/kg/day 3, 4, 5
- Short-term escalation: Some protocols allow 5-6 mg/kg/day initially, but this significantly increases toxicity risk 6
- Duration limit: Maximum 1-2 years continuous use due to cumulative nephrotoxicity 3, 5
The AAD/NPF guidelines emphasize that doses of 2.5-5.0 mg/kg/day should be used, with adjustments downward when clearance is achieved or toxicity occurs 3. The FDA label explicitly states the maximum dose should not exceed 4 mg/kg/day 5.
Rheumatoid Arthritis
- Starting dose: 2.5 mg/kg/day in two divided doses 5
- Maximum dose: 4 mg/kg/day 5
- Most patients can be managed with ≤3 mg/kg/day when combined with methotrexate 5
Atopic Dermatitis
- Recommended dose range: 3-5 mg/kg/day 4
- Limited-term use only (up to 1 year per FDA approval in psoriasis) 4
Critical Safety Thresholds
Nephrotoxicity risk stratification:
- <5 mg/kg/day: Rarely causes renal side effects 7
- ≥5 mg/kg/day: Substantially increased risk of structural kidney damage 1, 5
- >2 years duration: Risk of irreversible fibrosis increases dramatically regardless of dose 3, 5
In psoriasis patients treated for an average of 4.5 years, 71% had serum creatinine levels ≥30% above baseline, with most not returning to normal after dose reduction 3. Kidney biopsies showed cyclosporine-induced nephropathy in 21-30% of patients, with the majority receiving >5 mg/kg/day for >15 months 5.
Dose Adjustment Requirements
Reduce dose by 25-50% if:
- Serum creatinine increases ≥25% above baseline (psoriasis) or ≥30% above baseline (rheumatoid arthritis) 5
- Hypertension develops or worsens 5
- Other clinically significant toxicity occurs 5
Discontinue if:
- Serum creatinine increases ≥50% above baseline 5
- Creatinine elevation not reversible after two dose modifications 5
- Hypertension uncontrolled despite dose reduction 5
Special Populations
Elderly patients (>55 years):
- More than 3-fold higher risk of discontinuation due to toxicity 8
- Experience more frequent hypertension and renal dysfunction 6
- Consider alternative agents when possible 8
Pediatric dosing:
- 4-5 mg/kg/day starting dose for nephrotic syndrome 2
- 6 mg/kg/day used in some FSGS protocols, but higher toxicity 1
Monitoring Requirements
Frequency:
- Every 2 weeks for first 3 months, then monthly if stable 5
- More frequent monitoring required after dose increases 5
Parameters:
- Serum creatinine (on two occasions at baseline)
- Blood pressure (at least two measurements at baseline)
- Cyclosporine trough levels (target <150 ng/mL for nephrotic syndrome) 1
- CBC, liver function, lipids, magnesium, potassium, uric acid 3, 5
The evidence consistently demonstrates that exceeding 5 mg/kg/day substantially increases nephrotoxicity risk without proportional therapeutic benefit, making this the practical maximum for most clinical scenarios.